Stem cell transplantation for inflammatory bowel disease: practical and ethical issues

Open Access
Publisher Website
Google Scholar
Abstract
Intensive myelosuppressive or myeloablative chemotherapy followed by transplantation of stem cells derived directly from the bone marrow or from peripheral blood after suitable conditioning, has revolutionised the management of haematological malignancy and haemoglobinopathies. Because these manoeuvres cause significant and prolonged alterations in the body's immune system and function, stem cell transplantation has, in recent years, been used for severe cases of diseases that are believed to have an autoimmune basis. These diseases have included systemic sclerosis and multiple sclerosis but also rheumatoid arthritis, systemic lupus erythematosis, vasculitis, juvenile rheumatoid arthritis, and myasthenia gravis.1-7

This publication has 21 references indexed in Scilit: